DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Lawitz E, Freilich B, Link J. et al.
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus.
Journal of viral hepatitis 2015;
22: 1011-1019
We do not assume any responsibility for the contents of the web pages of other providers.